Open AccessRadiosynthesis and PET Bioimaging of 76Br-Bedaquiline in a Murine Model of Tuberculosis
Author(s) -
Alvaro A. Ordoñez,
Laurence Carroll,
Sudhanshu Abhishek,
Fernando Mota,
Camilo A. Ruiz-Bedoya,
Mariah H. Klunk,
Alok Singh,
Joel S. Freundlich,
Ronnie C. Mease,
Sanjay Jain
Publication year - 2019
Publication title -
acs infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.324
H-Index - 39
ISSN - 2373-8227
DOI - 10.1021/acsinfecdis.9b00207
Subject(s) - bedaquiline , radiosynthesis , biodistribution , positron emission tomography , medicine , tuberculosis , pharmacokinetics , nuclear medicine , ex vivo , parenchyma , in vivo , pathology , mycobacterium tuberculosis , pharmacology , biology , microbiology and biotechnology
Bedaquiline is a promising drug against tuberculosis (TB), but limited data are available on its intralesional pharmacokinetics. Moreover, current techniques rely on invasive tissue resection, which is difficult in humans and generally limited even in animals. In this study, we developed a novel radiosynthesis for 76 Br-bedaquiline and performed noninvasive, longitudinal whole-body positron emission tomography (PET) in live, Mycobacterium tuberculosis -infected mice over 48 h. After the intravenous injection, 76 Br-bedaquiline distributed to all organs and selectively localized to adipose tissue and liver, with excellent penetration into infected lung lesions (86%) and measurable penetration into the brain parenchyma (15%). Ex vivo high resolution, two-dimensional autoradiography, and same section hematoxylin/eosin and immunofluorescence provided detailed intralesional drug biodistribution. PET bioimaging and high-resolution autoradiography are novel techniques that can provide detailed, multicompartment, and intralesional pharmacokinetics of new and existing TB drugs. These technologies can significantly advance efforts to optimize drug dosing.